THE CART RECEPTOR

购物车接收器

• 批准号: 8172450
• 负责人: MICHAEL J KUHAR
• 金额: $ 2.74万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172450
• 关键词: Binding; Biological Assay; Cell Line; Cells; Cloning; Computer Retrieval of Information on Scientific Projects Database; Funding; Goals; Grant; Institution; Measures; Microarray Analysis; Orphan; PC12 Cells; Peptide Receptor; Pharmaceutical Preparations; Publications; Research; Research Personnel; Resources; Screening procedure; Source; System; United States National Institutes of Health; Work; cocaine- and amphetamine-regulated transcript protein; improved; receptor; receptor binding

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The last major part of the CART system to be identified is the CART receptor (it is possible that there are several receptors). Screening for medications related to CART peptides requires an ability to work with and express the receptor. While there have been several publications on the receptor, we have begun an intensive study with the goal of improving assays and a cloning of the receptor. The CART receptor binding assay has been standardized, and levels of specific binding in several cell lines have been measured. Specifically specific binding has been found in PC12 cells; when these cells differentiate, the binding increases. Microarray analysis has identified several possible receptors that are increased after differentiation and are therefore receptor candidates. Another approach to finding the CART peptide receptor has been to study known orphan receptors (an orphan is a receptor that is known, but whose activating substrate is unknown). Some orphan receptors have been expressed in cells, but as of this date, it is not yet clear if these are candidates. We continue to make significant progress identifying the CART peptide receptor(s).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 CART 系统最后一个待识别的主要部分是 CART 受体（可能有多个受体）。 筛选与 CART 肽相关的药物需要具有与受体结合并表达受体的能力。 虽然已经有几篇关于该受体的出版物，但我们已经开始了一项深入研究，目标是改进受体的测定和克隆。 CART 受体结合测定已经标准化，并且已经测量了几种细胞系中的特异性结合水平。 在 PC12 细胞中发现了特异性结合；当这些细胞分化时，结合就会增加。 微阵列分析已鉴定出几种可能的受体，这些受体在分化后增加，因此是受体候选者。 寻找 CART 肽受体的另一种方法是研究已知的孤儿受体（孤儿是已知的受体，但其激活底物未知）。 一些孤儿受体已在细胞中表达，但截至目前，尚不清楚这些受体是否是候选受体。 我们在识别 CART 肽受体方面继续取得重大进展。